Clinical Trials Logo

Clinical Trial Summary

the trial aims to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)


Clinical Trial Description

The purpose of this trial is to evaluate a new gadolinium-based contrast agent (GBCA) gadopiclenol injection for Central Nervous System (CNS) lesion detection and visualization by conventional steady-state CNS imaging. . This is a multi-center, international, prospective, double-blind, randomized, controlled,cross-over with comparator trial in male and female patients presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) who are scheduled to undergo a routine contrast-enhanced Magnetic Resonance Imaging (MRI) of the CNS. This trial will be conducted in approximately 40 centers worldwide. During the course of the trial, two MRIs will be obtained from each patient: one unenhanced and gadopiclenol-enhanced MRI; and one unenhanced and gadobutrol-enhanced MRI. MRI evaluations will be performed by on-site investigators and three independent off-site blinded readers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03996447
Study type Interventional
Source Guerbet
Contact
Status Completed
Phase Phase 3
Start date June 3, 2019
Completion date September 11, 2020

See also
  Status Clinical Trial Phase
Withdrawn NCT04096261 - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Completed NCT02633501 - P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Phase 2
Recruiting NCT06203015 - The Relations Among Endotoxin, Inflammatory Cytokines, Cognitive Markers and Brain MRI Changes in Subjects With Depressive Disorder
Active, not recruiting NCT04876638 - Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH) Phase 2
Completed NCT03639896 - Endothelial Injury Mechanism in Elderly Patients Undergoing Major Surgery Phase 4
Completed NCT02389738 - Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration Early Phase 1
Completed NCT03139682 - Microvascular Injury and Blood-brain Barrier Dysfunction as Novel Biomarkers and Targets for Treatment in Traumatic Brain Injury
Recruiting NCT05902039 - MRI Study of Blood-brain Barrier Function in CADASIL